Remnant Cholesterol and Neck Artery Thickness in Fatty Liver
Part of Heart & circulation, Hormones & metabolism clinical trials.
This study looks at whether a type of cholesterol called 'remnant cholesterol' and the thickness of the carotid artery (a neck artery) are linked to fatty liver disease. It may help doctors find better ways to prevent heart problems in people with fatty liver.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have been diagnosed with metabolic-associated fatty liver disease (MAFLD).
- You must not have any known heart disease, heart failure, or irregular heartbeat.
- You must not have liver cirrhosis (severe liver scarring).
- You must not have a current severe infection (sepsis).
- You must not have any type of cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether certain blood markers—including inflammation and fat levels—can help predict scarring in fatty livers. Understanding this connection may help doctors better identify patients at risk for serious liver damage.
This study looks at how fatty liver disease (a buildup of fat in the liver) relates to inflammation markers in your blood. Researchers want to understand this connection better to help patients with fatty liver disease in the future.
This study looks at how your thyroid might be linked to fatty liver disease (MAFLD). It aims to help researchers understand if thyroid problems play a role in this condition, which could lead to better treatments.
This study looks at whether the amount of fat in your liver, seen on an ultrasound, is linked to the severity of narrowing in your heart arteries. If you had a heart catheterization (angiography) and an abdominal ultrasound, your data may help researchers understand this connection.
This study follows people with a type of fatty liver disease called MAFLD to see if a reliable, painless ultrasound test called iLivTouch can help predict future liver problems. This could help doctors know who needs closer monitoring.
This trial is testing a new ultrasound method to measure fat in the liver for people with metabolic fatty liver disease (MAFLD). It may help understand how well ultrasound can show liver fat compared to a liver biopsy or MRI.
Hear when a new Detect the Significance of Remnant Cholesterol in Detection Severity of MAFLD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.